دورية أكاديمية
أعرض في EDS

Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.

التفاصيل البيبلوغرافية
العنوان: Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.
المؤلفون: Komegae EN; Immunoregulation Unit, Special Laboratory of Applied Toxinology, Butantan Institute, São Paulo, Brazil., Souza TA; Immunoregulation Unit, Special Laboratory of Applied Toxinology, Butantan Institute, São Paulo, Brazil., Grund LZ; Immunoregulation Unit, Special Laboratory of Applied Toxinology, Butantan Institute, São Paulo, Brazil., Lima C; Immunoregulation Unit, Special Laboratory of Applied Toxinology, Butantan Institute, São Paulo, Brazil., Lopes-Ferreira M; Immunoregulation Unit, Special Laboratory of Applied Toxinology, Butantan Institute, São Paulo, Brazil.
المصدر: PloS one [PLoS One] 2017 Feb 24; Vol. 12 (2), pp. e0171796. Date of Electronic Publication: 2017 Feb 24 (Print Publication: 2017).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Encephalomyelitis, Autoimmune, Experimental/*drug therapy , Fish Venoms/*chemistry , Immunologic Factors/*pharmacology , Peptides/*pharmacology , Spinal Cord/*drug effects , T-Lymphocytes, Regulatory/*drug effects, Amino Acid Sequence ; Animals ; Antigens, Differentiation/genetics ; Antigens, Differentiation/immunology ; Brazil ; Cuprizone ; Disease Models, Animal ; Encephalomyelitis, Autoimmune, Experimental/chemically induced ; Encephalomyelitis, Autoimmune, Experimental/immunology ; Encephalomyelitis, Autoimmune, Experimental/pathology ; Female ; Gene Expression Regulation ; Immunologic Factors/isolation & purification ; Interferon-gamma/genetics ; Interferon-gamma/immunology ; Interleukin-10/genetics ; Interleukin-10/immunology ; Interleukin-17/genetics ; Interleukin-17/immunology ; Macrophages/drug effects ; Macrophages/immunology ; Macrophages/pathology ; Matrix Metalloproteinase 9/genetics ; Matrix Metalloproteinase 9/immunology ; Mice ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/immunology ; Multiple Sclerosis/pathology ; Peptides/isolation & purification ; Perciformes/metabolism ; Spinal Cord/immunology ; Spinal Cord/pathology ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/pathology ; Th1 Cells/drug effects ; Th1 Cells/immunology ; Th1 Cells/pathology ; Th17 Cells/drug effects ; Th17 Cells/immunology ; Th17 Cells/pathology
مستخلص: The pathological condition of multiple sclerosis (MS) relies on innate and adaptive immunity. New types of agents that beneficially modify the course of MS, stopping the progression and repairing the damage appear promising. Here, we studied TnP, a small stable synthetic peptide derived from fish venom in the control of inflammation and demyelination in experimental autoimmune encephalomyelitis as prophylactic treatment. TnP decreased the number of the perivascular infiltrates in spinal cord, and the activity of MMP-9 by F4/80+ macrophages were decreased after different regimen treatments. TnP reduces in the central nervous system the infiltration of IFN-γ-producing Th1 and IL-17A-producing Th17 cells. Also, treatment with therapeutic TnP promotes the emergence of functional Treg in the central nervous system entirely dependent on IL-10. Therapeutic TnP treatment accelerates the remyelination process in a cuprizone model of demyelination. These findings support the beneficial effects of TnP and provides a new therapeutic opportunity for the treatment of MS.
References: J Neuroimmunol. 2012 Apr;245(1-2):1-7. (PMID: 22365083)
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):117-25. (PMID: 26492930)
Eur J Neurosci. 2002 Jan;15(1):19-32. (PMID: 11860503)
J Exp Med. 1996 Jul 1;184(1):19-29. (PMID: 8691133)
Nat Rev Immunol. 2006 May;6(5):358-70. (PMID: 16639429)
J Neurol Neurosurg Psychiatry. 2001 Dec;71 Suppl 2:ii16-9. (PMID: 11701779)
Nature. 2002 Nov 7;420(6911):78-84. (PMID: 12422218)
J Intern Med. 2014 Apr;275(4):350-63. (PMID: 24444048)
PLoS One. 2014 Jun 04;9(6):e99068. (PMID: 24896098)
Nat Med. 2009 Jul;15(7):766-73. (PMID: 19561618)
J Immunol. 2008 Jun 1;180(11):7414-22. (PMID: 18490741)
Cell Rep. 2015 Feb 24;10(7):1040-54. (PMID: 25704809)
Trends Mol Med. 2010 Feb;16(2):58-68. (PMID: 20159585)
Neurosci Biobehav Rev. 2014 Nov;47:485-505. (PMID: 25445182)
Blood. 2009 Apr 30;113(18):4240-9. (PMID: 19171879)
Eur J Immunol. 1992 Jul;22(7):1757-63. (PMID: 1378016)
N Engl J Med. 2017 Jan 19;376(3):209-220. (PMID: 28002688)
Brain. 2002 May;125(Pt 5):952-60. (PMID: 11960885)
Lancet Neurol. 2014 Jul;13(7):700-9. (PMID: 24852507)
Inflamm Res. 2010 Sep;59(9):679-87. (PMID: 20454830)
Lancet. 2004 May 15;363(9421):1607-8. (PMID: 15145635)
J Exp Med. 2010 Aug 30;207(9):1891-905. (PMID: 20696698)
Nat Rev Immunol. 2007 Nov;7(11):904-12. (PMID: 17917672)
Ann Neurol. 2005 Dec;58(6):840-6. (PMID: 16283615)
Mult Scler. 2012 Feb;18(2):143-52. (PMID: 22312009)
J Neuroimmunol. 1998 Dec 1;92(1-2):38-49. (PMID: 9916878)
Pract Neurol. 2012 Feb;12(1):25-35. (PMID: 22258169)
J Exp Med. 2011 Nov 21;208(12):2465-76. (PMID: 22025301)
Eur J Immunol. 2015 Jan;45(1):180-91. (PMID: 25329858)
Neurology. 2001 Mar 27;56(6):702-8. (PMID: 11288751)
Eur J Immunol. 1995 Jul;25(7):1951-9. (PMID: 7621871)
J Immunol. 1998 Oct 1;161(7):3299-306. (PMID: 9759845)
Neurology. 2005 Apr 26;64(8):1336-42. (PMID: 15851719)
Mayo Clin Proc. 2014 Feb;89(2):225-40. (PMID: 24485135)
Histol Histopathol. 2011 Dec;26(12 ):1585-97. (PMID: 21972097)
Brain Res. 2005 Feb 21;1035(1):24-31. (PMID: 15713273)
Brain Res. 2009 Aug 4;1283:127-38. (PMID: 19524552)
PLoS One. 2010 Sep 01;5(9):null. (PMID: 20824132)
Nat Med. 2010 Apr;16(4):406-12. (PMID: 20348925)
Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):3960-5. (PMID: 27035952)
Nat Immunol. 2002 Oct;3(10):944-50. (PMID: 12244307)
J Immunol. 2014 Aug 1;193(3):1047-54. (PMID: 24958901)
Brain Pathol. 2007 Apr;17(2):243-50. (PMID: 17388955)
Brain Res Bull. 1996;41(3):131-41. (PMID: 8886382)
Nat Neurosci. 2010 Mar;13(3):319-26. (PMID: 20154684)
J Neuroimmunol. 2002 Sep;130(1-2):32-45. (PMID: 12225886)
CNS Neurol Disord Drug Targets. 2012 Aug;11(5):497-505. (PMID: 22583434)
J Neurosci. 2006 Dec 6;26(49):12672-81. (PMID: 17151270)
J Immunol. 2011 Feb 15;186(4):1887-90. (PMID: 21289312)
المشرفين على المادة: 0 (Antigens, Differentiation)
0 (Fish Venoms)
0 (Immunologic Factors)
0 (Interleukin-17)
0 (Peptides)
0 (monocyte-macrophage differentiation antigen)
130068-27-8 (Interleukin-10)
5N16U7E0AO (Cuprizone)
82115-62-6 (Interferon-gamma)
EC 3.4.24.35 (Matrix Metalloproteinase 9)
تواريخ الأحداث: Date Created: 20170225 Date Completed: 20170817 Latest Revision: 20190208
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC5325231
DOI: 10.1371/journal.pone.0171796
PMID: 28235052
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0171796